NCT01818921View on ClinicalTrials.gov

An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
ObesityOver-weightPrader-Willi Syndrome
Interventions
DRUG

ZGN-440 sterile diluent

ZGN-440 sterile diluent/placebo

DRUG

1.2 mg ZGN-440 for injectable suspension

1.2 mg beloranib

DRUG

1.8 mg ZGN-440 for injectable suspension

1.8 mg beloranib

Trial Locations (1)

32610-0296

University of Florida, Gainesville

All Listed Sponsors
lead

Zafgen, Inc.

INDUSTRY

NCT01818921 - An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome | Biotech Hunter | Biotech Hunter